Aedifica S.A. AEDFF OTC · Real estate · Belgium
$72.13 +0.00% +$0.00
Summary
67 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 132 EUR is left as net profit.
- The share price is below the Bulios Fair Price.
- Revenue grew by 9.8% a year over the last 3 years.
- Analysts expect revenue to grow by 68% this fiscal year.
What to watch
- Earnings per share fell by 16% a year over the last 3 years.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 8.5 EUR for 1 EUR of yearly profit. Over the last five years it was 28.5 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 9.8% a year. For the next fiscal year analysts expect revenue to grow by 68%. Earnings per share fell by 16% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 8.3 EUR
- Sales and administration 6.1 EUR
- Taxes and other -46 EUR
- Net profit 132 EUR
Net profit, industry median (REIT - Healthcare Facilities) 15 EUR
Out of every 100 EUR of revenue, 132 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenIts debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 4.60%
- Paid out of profit
- 39%
- Raised in a row
- 1 year
You receive $3.32 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 0
- Sell 1
Today's price within the analysts' price targets
The average target of $75 is 4.0% above today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.